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Abstract: Aims: Corona virus disease 2019 (COVID-19) is a still growing pandemic, causing many deaths
and socio-economic damage. Elevated expression of the SARS-CoV-2 entry receptor ACE2 on cardiac
cells of patients with heart diseases may be related to cardiovascular burden. We have thus analysed
cardiovascular and inflammatory microRNAs (miRs), sensitive markers of cardiovascular damage, in crit-
ically ill, ventilated patients with COVID-19 or Influenza associated acute respiratory distress syndrome
(Influenza-ARDS) admitted to intensive care unit (ICU) and healthy controls. Methods and results:
Circulating miRs (miR-21, miR-126, miR-155, miR-208a and miR-499) were analyzed in a discovery co-
hort consisting of patients with mechanically-ventilated COVID-19 (n = 18) and healthy controls (n =
15). A validation study was performed in an independent cohort of mechanically-ventilated COVID-19
patients (n = 20), Influenza-ARDS patients (n = 13) and healthy controls (n = 32). In both cohorts
RNA was isolated from serum and cardiovascular disease/inflammatory-relevant miR concentrations were
measured by miR-specific TaqMan PCR analyses. In both the discovery and the validation cohort, serum
concentration of miR-21, miR-155, miR-208a and miR-499 were significantly increased in COVID-19 pa-
tients compared to healthy controls. Calculating the area under the curve (AUC) using ROC-analysis
miR-155, miR-208a and miR-499 showed a clear distinction between COVID-19 and Influenza-ARDS
patients. Conclusion: In this exploratory study, inflammation and cardiac myocyte-specific miRs were
upregulated in critically ill COVID-19 patients. Importantly, miR profiles were able to differentiate be-
tween severely ill, mechanically-ventilated Influenza-ARDS and COVID-19 patients, indicating a rather
specific response and cardiac involvement of COVID-19. Keywords: ARDS; COVID-19; SARS-CoV-2;
biomarker; influenza; microRNA.
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Corona virus disease 2019 (COVID-19) is a still growing pandemic, causing many deaths and 
socio-economic damage. Elevated expression of the SARS-CoV-2 entry receptor ACE2 on cardiac 
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cardiovascular and inflammatory microRNAs (miRs), sensitive markers of cardiovascular damage, in 
critically ill, ventilated patients with COVID-19 or Influenza associated acute respiratory distress 
syndrome (Influenza-ARDS) admitted to intensive care unit (ICU) and healthy controls.  
Methods and Results 
Circulating miRs (miR-21, miR-126, miR-155, miR-208a and miR-499) were analyzed in a 
discovery cohort consisting of patients with mechanically-ventilated COVID-19 (n=18) and healthy 
controls (n=15). A validation study was performed in an independent cohort of mechanically-
ventilated COVID-19 patients (n=20), Influenza-ARDS patients (n=13) and healthy controls (n=32). 
In both cohorts RNA was isolated from serum and cardiovascular disease/inflammatory-relevant miR 
concentrations were measured by miR-specific TaqMan PCR analyses. 
In both the discovery and the validation cohort, serum concentration of miR-21, miR-155, 
miR-208a and miR-499 were significantly increased in COVID-19 patients compared to healthy 
controls. Calculating the area under the curve (AUC) using ROC-analysis miR-155, miR-208a and 
miR-499 showed a clear distinction between COVID-19 and Influenza-ARDS patients. 
Conclusion  
In this exploratory study, inflammation and cardiac myocyte-specific miRs were upregulated 
in critically ill COVID-19 patients. Importantly, miR profiles were able to differentiate between 
severely ill, mechanically-ventilated Influenza-ARDS and COVID-19 patients, indicating a rather 
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Introduction: 
Corona virus disease 2019 (COVID-19) is still a rapidly growing pandemic disease, which has 
claimed already more than 1.5 million lives worldwide. Despite massive efforts by the scientific 
community and enormous accumulation of new insights, the complexity of COVID-19 caused by the 
novel corona virus SARS-CoV-2 is still far from being completely understood. Infection with this β-
genus SARS-CoV-2 can lead to the potentially lethal COVID-19, primarily characterized by 
pneumonia which can progress into acute respiratory distress syndrome (ARDS). A relatively high 
incidence of cardiac complications along with respiratory manifestations in COVID-19 patients has 
raised concerns, and might be significantly contributing to overall mortality 
1-3
. Moreover, multiple 
organ dysfunctions in infected patients might be triggered and aggravated by a maladaptive immune 
response that causes systemic inflammatory response associated with endothelial dysfunction 
4-7
.  
As per the initial understanding, patients with pre-existing cardiovascular diseases are at 
higher risk for severe courses of COVID-19 presumably related to higher susceptibility to endothelial 
injury due to their pre-existing vascular burden or higher expression of its entry receptor ACE2 in 
cardiovascular cells including myocytes, fibrocytes and endothelial cells 
8,9
. The spectrum of 
cardiovascular manifestations ranges from elevated markers of cardiovascular damage such as 
troponins to severe arrhythmias and even myocardial infarctions 
3,10
. Therefore, analysing markers 
pertaining to cardiovascular properties in COVID-19 patients might be helpful in predicting 
unfavourable outcome and complications. 
MicroRNAs (miRs) are short noncoding ribonucleic acids which play essential regulatory 
roles in various cellular functions and disease processes. Moreover, their ease of detection in our 
circulatory system has established them as potential sensitive disease biomarkers especially in the 
cardiovascular context 
11-15
. Therefore, we sought to identify changes in selected miRs; cardiovascular 
disease and inflammation-associated (miR-155), myocyte-associated miRs (myomiRs miR-499 and 
miR-208a), fibromiRs (miR-21) and endothelial miRs (miR-126) in the blood from mechanically-
ventilated ICU patients with COVID-19 associated pneumonia in comparison to Influenza-ARDS 
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Methods 
Clinical data: 
Clinical data (demographics, cardiovascular risk factors, cardiac premedication, laboratory, 
organ function scores at time of sampling, clinical outcomes) and serum were obtained from ICU 
patients with severe COVID-19 pneumonia requiring invasive ventilation (onepatient received high 
flow nasal oxygen therapy at time of sampling but was intubated shortly after) and severe, 
mechanically-ventilated influenza ARDS patients (Influenza-ARDS group). The investigation 
conforms to the principles outlined in the 1964 Declaration of Helsinki and later amendments 
16
. All 
patients or their health representatives provided written consent. Healthy volunteers were chosen as 




RNA was isolated from 100 µL of serum using the miRNeasy Serum/Plasma Kit (Qiagen, as 
described by the manufacturer. Synthetic cel-miR-39-3p (1.6x10
8
 copies/µl) (Qiagen) was spiked-in 
before RNA isolation for normalization in subsequent quantitative real-time PCR (qRT-PCR). RNA 
was eluted from the columns with 30 µL of water 
12,17
. The RNA was treated with heparinase to 
remove traces of heparin known to interfere with PCR reactions. 
 
PCR-based analysis of miRs: 
The isolated RNA was reverse transcribed to complementary DNA (cDNA) utilising TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems) following manufactures guidelines. RT-
qPCR was performed with specific TaqMan miR assays (Applied Biosystems®) for Cel-miR-39, hsa-
miR-21-5p, hsa-miR-126-3p, hsa-miR-155-5p, hsa-miR-208a-3p and hsa-miR-499-5p on a Viia7 
system (Thermo Fisher Scientific). miRs with Cq≥36 were deemed to be undetected and set to Cq=36. 
Relative miR concentrations were calculated using the 2
-dCq
 method (dCq = Cq[miR]−Cq[Cel-miR-
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Statistical analysis:  
Statistical analysis of miR concentrations between the two groups was performed via Mann-
Whitney test in the discovery cohort. In the validation cohort Dunn’s multiple comparisons test was 
used to compare healthy controls, Influenza-ARDS and COVID-19 patients. For group discrimination 
by levels of selected miRs receiver operating characteristic (ROC) curves were used and the area 
under the curve (AUC) was calculated. Clinical characteristics depending on miR levels were 
compared by Chi² or Wilcoxon-U-Test, as appropriate after subgrouping by median concentration of 
individual miRs. All analyses and graph production were performed using STATA V16.1 (USA) and 
GraphPad Prism 9 (USA).  
Results 
In this exploratory study we initially compared serum miR concentrations in critically ill 
COVID-19 patients with that of healthy individuals as a discovery cohort. The control group consisted 
of 15 subjects (median age 31 years, 93% male) while the COVID-19 group comprised 18 subjects 
(median age 59 years, 94% male). Demographic data of discovery cohort are described in (Table 1, 
online data supplement). In the discovery cohort miR-21, miR-155, miR-208a and miR-499 were 
significantly upregulated in COVID-19 patients compared to healthy controls whereas miR-126 levels 
were significantly decreased (Figure 1).  
For validation, we recruited an independent cohort of mechanically-ventilated COVID-19 
patients (n=20, median age 59.5 years, 70% male), as well as invasively-ventilated Influenza-ARDS 
patients (n=13, median age 56 years, 85% male) with similar respiratory compromise (Table 1) and 
reasonably age-matched healthy controls (n=32; median age 50 years; 62.5% male). When comparing 
the cardiovascular risk factors between the COVID-19 and Influenza-ARDS groups, with the 
exception of smoking history no significant differences in the number of diabetic, arterial 
hypertension, dyslipidemia and obesity were observed (Table 1). No significant differences in cardiac 
premedication (use of ACE inhibitors, AT1 inhibitors, beta blockers, diuretics, calcium antagonists 
and aldosterone antagonists) were found (Table 1). Procalcitonin, LDH, Troponin-T, Creatine kinase 
and SOFA score were significantly higher in the Influenza-ARDS group compared to COVID-19 
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In line with the validation cohort, miR-21 was increased in the COVID-19 group compared to 
healthy controls and to Influenza-ARDS patients (Figure 1&2 A). Changes in miR-126 concentration 
could not be confirmed in the validation cohort (Figure 1&2 B). Upregulation of miR-155 and miR-
499 in COVID-19 patients was confirmed in the second cohort both compared to healthy controls and 
Influenza-ARDS patients (Figure 1&2 C&E), whereas miR-208a was upregulated in both severe 
COVID-19 and Influenza-ARDS group compared to healthy controls (Figure 1&2 D). 
ROC analyses of inflammation and cardiac associated miRs miR-155, miR-208a and miR-499 
showed a strong discrimination between COVID-19 and Influenza-ARDS by these markers of 
myocardial damage (AUC: 1.000 (miR155); 0.796 (miR-208a); 0.865 (miR-499)) (Figure 3). 
Stratification into low and high miR concentrations divided by the median concentration 
revealed an association of lower miR-21 levels with more ventilation and vasopressor days as well as a 
higher rate of ECMO and renal-replacement therapy (Table 2). Higher miR-208a and miR-499 levels 
were associated with elevated procalcitonin and lactate (Table 2). 
 
Discussion 
In this exploratory study, we aimed to investigate altered levels of circulating cardiovascular 
and inflammatory miRs in severe COVID-19 patients requiring invasive ventilation to identify 
biomarkers for myocardial damage and disease severity. The rationale for the design of this study was 
the well-described association of miR-155 with inflammation, miR-208a and miR-499 with 
myocardial/cardiomyocyte damage, and miR-21 and miR-126 with cardiac fibroblast and endothelial 
cell dysfunction, respectively 
18
. To our knowledge, this is the first study reporting the interlink of miR 
levels in blood of COVID-19 patients and clinical parameters. Our study identified significantly 
altered levels of cardiac-associated miRs in COVID-19 patients indicating a strong association of 
COVID-19 with cardiovascular ailments and respective biomarkers. 
 In order to strengthen the quality and significance of the exploratory study, we performed our 
analysis across two waves of the COVID-19 pandemic to include a broader pool of patient samples. 
We initially analyzed a discovery cohort during the first wave of COVID-19 and then, after recruiting 
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Except for miR-126, all miRs were consistently upregulated in the COVID-19 group compared to the 
healthy controls in both the discovery and the validation cohort. In line with the clinical picture of the 
disease, inflammatory miRs, such as miR-155 
19
 and heart-muscle specific miRs, also called 
myomiRs, such as miR-208a 
20
 and miR-499 
20,21
 were significantly upregulated in COVID-19 
patients. Interestingly, the altered levels of miR-155 and miR-499 could further distinguish between 
COVID-19 and Influenza-ARDS groups, even though both the diseases are phenotypically very 
similar. With the levels of inflammation associated miR-155 being highest at the site, the markedly 
elevated levels in COVID-19 might be reflective of the since widely-appreciated endothelialitis, which 
is COVID-19-specific 
22
. In line with this, miR-126 which is known to be protective from endothelial 
damage and deprived in chronic cardiovascular disease
23
 was decreased in our discovery cohort, 
albeit this finding was not reproducible in the validation cohort.  Within the COVID-19 group, the 
patients with higher miR-208a and miR-499 also had a higher Procalcitonin and lactate levels. 
However, this clinical correlation should not be overestimated as Procalcitonin and lactate were 
relatively low on average. A correlation between deregulated miRNA levels and ECMO support has 
also been observed previously, however, whether ECMO support caused the miR deregulation or miR 
deregulation called for ECMO support is not very clear 
24
. In this regard, it has been demonstrated that 
the use of ECMO is not associated with significant changes in circulating miRs within 24 hours before 
and after ECMO-implantation 
25
.  
Interestingly, fibrosis-associated miR-21 
11
 was found to be increased in acute COVID-19 
compared to healthy controls and Influenza-ARDS patients. The upregulation of miR-21, miR-155, 
miR-208a and miR-499 in COVID-19 survivors might be a predictor of chronic myocardial damage 
and inflammation. Of note, despite troponin levels being higher in the Influenza-ARDS group, 
myocardial specific miR-208a and miR-499 were more upregulated in COVID-19. In this context, a 
recent cardiovascular magnetic resonance (CMR) imaging study in patients recently recovered from 
SARS-CoV2 infection provided alarming results. In 78 out of 100 patients CMR abnormalities were 
found and 60 patients presented with ongoing myocardial inflammation while high sensitive troponin 
levels were only elevated in 5% of the cohort 
26
, indicating troponin is not a useful marker of 
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preexisting conditions and severity and overall course of COVID-19 
26
. This highlights the need for 
easily accessible biomarkers, such as circulating miRs, which may provide predictive information on 
potential long-term cardiovascular consequences. Overall, we believe that the significance of this 
study is strengthened by the fact, that patients in both the COVID-19 group and the Influenza-ARDS 
group had a similar cardiac pre-existing disease spectrum prior to hospitalization, but the miR 
concentration is significantly different in severe ARDS. This confirms that unlike influenza, which 
mainly triggers a pulmonary response, COVID-19 infection triggers multi-organ involvement with 
inflammation, endothelial cell damage and cardiac involvement. 
Although this study encompasses a rather small patient population, our exploratory approach 
divided in two independent cohorts provides important insights into the pathophysiological aspects of 
miRs in COVID-19. These should serve as a foundation for larger studies and also serve to analyze the 
long-term course of COVID-19 patients. 
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Figure Legend 
Figure 1. Levels of the indicated miRs in healthy controls and COVID-19 patients. Data are 
presented as dot plots and mean ± standard deviation (SD). Mann-Whitney test was used for statistical 
comparison. 
Figure 2. Levels of the indicated miRs in healthy controls, Influenza-ARDS and COVID-19 
patients. Data are presented as dot plots and mean ± standard deviation (SD).  Dunn’s multiple 
comparisons test was used for statistical comparison.  
Figure 3. ROC curve analysis of multiple microRNAs (miR-155, miR-208a, miR-499) was 
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Table 1. Demographics Validation Cohort 
Characteristics COVID-19 (n=20) Influenza-ARDS 
(n=13) 
p-value 
Age (y), median (IQR) 59.5 (46-68) 56 (49-58) 0.554 
Male (%)  14 (70)  11 (85) 0.338 
Body mass index (kg/m²), median (IQR) 29.4 (25.7-33.4) 25 (24.5-29.2) 0.107 
Cardiovascular risk factors      
Diabetes (%)  6 (30)  0 (0) 0.060 
Arterial hypertension (%)  11 (55)  5 (38) 0.481 
Dyslipidemia (%)  3 (15)  4 (31) 0.393 
Obesity (%)  5 (25)  4 (31) >.999 
Ever smoker (%)  0 (0)  6 (46) 0.002 
Cardiac premedication      
ACE inhibitor (%)  3 (15)  1 (8) 0.638 
AT1 inhibitor (%)  2 (10)  3 (23) 0.360 
Beta blocker (%)  5 (25)  3 (23) >.999 
Diuretic (%)  4 (20)  1 (8) 0.625 
Calcium antagonist (%)  2 (10)  2 (15) >.999 
Aldosterone antagonist (%)  0 (0)  1 (8) 0.394 
Basal echocardiographic data      
No. of existing data (%)  7 (35)  8 (62)  
Preserved LVEF (%)  7 (100)  8 (100) >.999 
LV hypertrophy (%)  3 (43)  3 (38) >.999 
Laboratory at time of sampling      
CRP (mg/L), median (IQR) 123 (92-197) 197 (141-296) 0.069 
Procalcitonin (ng/L), median (IQR) 0.45 (0.2-1.0) 3.55 (1.55-9.55) <.001 
IL-6 (ng/L), median (IQR) 98 (32-304) -   
Ferritin (µg/L), median (IQR) 1513 (1065-2267) 1613 (620-5017) 0.910 
Leukocytes (gpt/L), median (IQR) 8.8 (7.1-16.4) 8.6 (6.5-12.6) 0.407 
Lactate (mmol/L), median (IQR) 1.7 (1.3-2.0) 1.2 (1.0-1.8) 0.154 
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LDH (U/L), median (IQR) 433 (358-572) 550 (515-908) 0.004 
NT-pro-BNP (ng/L) 482 (278-803) 1211 (380-2611) 0.068 
Troponin T (ng/L), median (IQR) 12 (6-25) 42 (14-110) 0.011 
Creatine kinase (U/L), median (IQR) 301 (97-589) 918 (721-1846) 0.003 
paO2 / FiO2 (mmHg), median (IQR) 97 (64-153) 83 (60-100) 0.137 
SOFA score at day of sampling (IQR) 8 (6-9) 11 (10-12) 0.001 
Treatment modalities at time of 
sampling 
     
Invasive ventilation (%)  18 (90)  13 (100) 0.239 
PEEP (mbar), median (IQR) 14 (10-16) 15 (14-16) 0.483 
Pmax (mbar), median (IQR) 28 (25-30) 26 (25-28) 0.640 
ECMO (%)  3 (15)  5 (38) 0.124 
Vasopressor use (%)  14 (70)  12 (92) 0.423 
Noradrenaline dose (µg/kg/min), 
median (IQR) 
0.175 (0.057-0.267) 0.306 (0.212-0.563) 0.030 
Treatment modalities and outcomes 
during ICU stay 
     
Renal replacement therapy (%)  6 (30)  8 (62) 0.073 
ECMO (%)  8 (40)  7 (54) 0.435 
ECMO days, median (IQR) 9 (7-15) 12 (3-20) 0.799 
ICU days, median (IQR) 18 (12-26) 18 (15-21) 0.920 
Vasopressor days, median (IQR) 8 (3-12) 8 (4-13) 0.792 
Ventilation days, median (IQR) 13 (8-20) 15 (9-17) 0.736 
28-day ICU mortality (%)  2 (10)  5 (38) 0.051 
 
y – years; IQR – interquartile range; ACE – Angiotensin-converting enzyme; AT1 – angiotensin II 
receptor type 1; No. – number; IL-6 – interleukin-6; CRP – C-reactive protein; paO2 – arterial 
partial pressure of oxygen; FiO2 – Fraction of inspired oxygen; SOFA score – sequential organ 
failure assessment score; PEEP – positive end expiratory pressure; Pmax – pressure maximum; 
ECMO – extracorporeal membrane oxygenation; ICU – intensive care unit. 
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Table 2.  Differences in clinical and laboratory data at time of sampling between COVID-19 patients of validation cohort with high/low* 













 p-value (p<0.1; p<0.05; p<0.01); ↑ / ↓=increased / decreased in reference group 
ICU outcomes      
  Ventilation days ↑ 0.040 0.422 0.752 0.269 0.563 
  Vasopressor days ↑ 0.015 0.183 0.727 0.644 0.644 
  Vasopressor dose 0.259 0.209 0.620 0.755 0.606 
Laboratory      
  IL-6 0.128 0.197 0.305 0.239 0.149 
  CRP ↑ 0.096 ↑ 0.082 0.353 0.393 0.481 
  PCT  0.790 0.889 0.961 ↑ 0.061 ↑ 0.026 
  Ferritin 0.199 0.940 0.740 0.880 0.199 
  Thrombocytes 0.542 0.565 0.469 0.494 0.542 
  Bilirubin 0.826 0.645 0.983 0.617 0.535 
  D-Dimer 0.360 0.573 0.762 0.122 0.136 
  Lactate 0.616 0.671 0.270 ↑ 0.007 ↑ 0.030 
 Troponin T 0.855 0.233 ↓ 0.060 0.829 0.537 
 Creatine kinase 0.218 0.123 0.739 0.105 0.436 
 NT-Pro-BNP 0.971 0.684 0.280 0.684 0.579 
  LDH ↓ 0.049 ↓ 0.082 1.000 0.631 1.000 
Treatments at any time      
  Dialysis ↑ 0.051 0.329 0.329 0.329 1.000 
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